TOP HEADLINES

FEATURED STORY

Catalent posts flat revenue as currency woes bite into growth

Catalent Pharma Solutions remained stagnant in its fiscal second quarter, as global currency fluctuations undid baseline growth in its banner businesses.

Recipharm commits $45M to counteract fake drugs

Contract drugmaker Recipharm is promising to spend $45 million (€40 million) over the next three years to improve drug traceability in an effort to comply with new regulations and combat the rise of fake medicines.

Quintiles bets on a big 2016 as revenue rolls in

Quintiles, the world's largest CRO, is expecting its revenue to jump as much as 8.5% in 2016 on the heels of a record year.

Genomics England picks Icon as its first CRO partner

Icon has become the first contract research company to help manage the reams of big data coming from the U.K.'s unique private-public partnership Genomics England.

Chinese CRO Pharmaron acquires U.K.-based Quotient Bioresearch

Beijing, China-based contract research organization Pharmaron has snapped up fellow CRO Quotient Bioresearch as it looks to broaden its reach both technically and geographically.

MORE NEWS

From Our Sister Sites

FierceMedicalDevices

Pfizer Consumer Healthcare announced the launch of joint health and wellness innovation program that will enable 10 med tech startups to utilize the San Francisco office of tech industry incubator Galvanize.

FiercePharma

India's Sun Pharmaceutical saw its sales in the U.S., its largest market, continue to fall as problems with a key plant in India have yet to be resolved. U.S. sales were off 11% to $486 million in the quarter ended Dec. 31, 2015, India's largest drugmaker reported today.